Related Experiment Video
Updated: Jul 12, 2026

Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis
Published on: November 21, 2013
Prevalence and frequency of haematological testing in patients initiating clozapine in the USA
Katsiaryna Bykov1, Mufaddal Mahesri2, Krista F Huybrechts2
1Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA kbykov@bwh.harvard.edu.
Insights
Hematological testing for clozapine initiation was underutilized before treatment and in the first six months. Testing rates improved after six months, aligning with recommendations.
Area of Science:
- Pharmacovigilance
- Clinical Pharmacy
- Health Services Research
Background:
- Clozapine initiation in the USA previously mandated the Clozapine Risk Evaluation and Mitigation Strategy (REMS) for haematological testing.
- Despite REMS elimination in June 2025, clinical guidelines for clozapine testing persist.
- Adherence to clozapine testing protocols in real-world practice remains under-examined.
Purpose of the Study:
- To determine the prevalence and frequency of haematological testing in patients prescribed clozapine.
- To evaluate testing rates before clozapine initiation and during the initial 24 months of therapy.
Main Methods:
- A retrospective cohort study analyzed data from three US health insurance claims databases (2000-2022).
- Assessed the proportion of patients with pre-initiation testing (within 60 days) and testing frequency (tests per 30 days) during the first 24 months of clozapine treatment.
- Identified tests using billing codes; assumed hospitalized patients received testing.
Main Results:
- Out of 62,003 clozapine initiations, 71% had pre-initiation testing.
- Mean testing rates were 2.2 tests/30 days (months 0-6), 2.0 tests/30 days (months 7-12), and 1.5 tests/30 days (months 13-24).
- Testing rates were lower than expected before initiation and during the first six months of therapy.
Conclusions:
- Haematological testing adherence before clozapine initiation and in early treatment phases was suboptimal.
- Testing frequency met recommendations in later treatment stages (after 6 months).
- Further investigation is needed to understand the reasons for underutilization of recommended clozapine testing, particularly in the initial treatment period.
Background:
Until June 2025, individuals initiating clozapine in the USA were required to undergo routine haematological testing in accordance with the Clozapine Risk Evaluation and Mitigation Strategy (REMS) programme. Although the Clozapine REMS programme was eliminated in June 2025, clinical and prescribing recommendations on testing remained intact. Little is known, however, about adherence to testing requirements in practice.
Objective:
The aim of this study was to assess the prevalence and frequency of haematological testing in patients on clozapine.
Methods:
A cohort study using three US health insurance claims databases (1 January 2000-31 March 2022) assessed (1) proportion of individuals with at least one haematological test (white blood cell count with differential) prior to clozapine initiation and (2) frequency of testing (number of tests per 30 days of follow-up) during months 0-6, 7-12 and 13-24 of clozapine therapy. Tests were identified based on billing codes; patients hospitalised during the assessment period were assumed to have received testing.
Findings:
A total of 62 003 clozapine initiations (mean (SD) age, 36 (15) years; 57% male) were identified, of which 71% were preceded by testing within 60 prior days. The mean (SD) testing rate while on therapy was 2.2 (1.8) tests per patient for each 30-day period during the first 6 months of treatment, 2.0 (1.8) tests per 30 days during months 7-12 and 1.5 (1.4) tests per 30 days during months 13-24.
Conclusions:
In this study of individuals initiating clozapine in the USA, haematological testing was completed at a lower-than-expected rate prior to clozapine initiation and during the first 6 months of treatment but was in accordance with testing requirements thereafter.
Clinical Implications:
Although clozapine drug labelling recommends routine haematological testing, especially during the first 6 months of treatment, such testing may not consistently occur. Reasons for less-than-recommended testing frequency should be further investigated.
Related Concept Videos
Psychosis: Goals of Pharmacotherapy
Psychosis and Antipsychotic Drugs: Overview
Prevalence and Incidence
Prevalence indicates the proportion of individuals in a population who have a specific disease or health condition at a...
Drug Therapy
Antianxiety Medications